Skip to main content

Table 4 Overall improvement at 1 month, 2 as well as 6 months after repeated tender-point injections with active substance (GRA) or control substance (CTR) in 40 patients with myofascial temporomandibular disorders

From: Repeated tender point injections of granisetron alleviate chronic myofascial pain - a randomized, controlled, double-blinded trial

 

1 month

2 months

6 months

 

GRA (n = 20)

CTR (n = 18)

GRA (n = 16)

CTR (n = 8)

GRA (n = 10)

CTR (n = 5)

Overall improvement

      

 “No change” to “Worse”

4

4

3

3

1

2

 “Better” to “Symptom-free”

16

14

13*

5

9*

3

  “Better”

9

8

6

2

3

1

  “Much better” or “Symptom-free”

7

9

7

3

6

2

  1. GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden); *Significant difference compared to the CTR-group (χ 2-test; 2 months: P = 0.005, 6-months: P < 0.001)